FDAnews
www.fdanews.com/articles/72197-cypress-bioscience-files-100-million-stock-shelf

Cypress Bioscience Files $100 Million Stock Shelf

May 11, 2005

Cypress Bioscience may periodically sell up to $100 million in common stock, according to a regulatory filing on Tuesday. The San Diego, Calif.-based biopharmaceutical company said it plans to use the proceeds for clinical trials, research and development, and other general corporate purposes, according to the filing with the U.S. Securities and Exchange Commission. Under a shelf registration, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of the sale.

Reuters (http://www.reuters.com/newsArticle.jhtml?storyID=8446011)